

Once-Daily, High-Concentration MMX Mesalamine in A

Gastroenterology

132, 66-75

DOI: [10.1053/j.gastro.2006.10.011](https://doi.org/10.1053/j.gastro.2006.10.011)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Current and future therapies for inflammatory bowel disease. Expert Review of Gastroenterology and Hepatology, 2007, 1, 89-100.	1.4	0
2	Once-Daily, High-Concentration MMX Mesalamine in Active Ulcerative Colitis. Yearbook of Gastroenterology, 2007, 2007, 107-109.	0.1	0
3	Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet, The, 2007, 369, 1641-1657.	6.3	1,593
4	Inflammatory Bowel Diseases in the Elderly. Clinics in Geriatric Medicine, 2007, 23, 809-821.	1.0	11
5	Novel therapies based on enhancement of gut innate immunity in inflammatory bowel disease. Expert Opinion on Therapeutic Patents, 2007, 17, 1423-1441.	2.4	1
6	Effect of Once- or Twice-Daily MMX Mesalamine (SPD476) for the Induction of Remission of Mild to Moderately Active Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2007, 5, 95-102.	2.4	264
7	Current Medical Therapy for Chronic Inflammatory Bowel Diseases. Surgical Clinics of North America, 2007, 87, 697-725.	0.5	17
8	Delayed-Release Multi Matrix System (MMX [®] , [®]) Mesalazine. Drugs, 2007, 67, 2635-2642.	4.9	18
9	Delayed-Release Multi Matrix System (MMX [®] , [®]) Mesalazine in Ulcerative Colitis. Drugs, 2007, 67, 2643-2644.	4.9	0
10	Delayed-Release Multi Matrix System (MMX [®] , [®]) Mesalazine in Ulcerative Colitis. Drugs, 2007, 67, 2643-2644.	4.9	0
11	Mild-to-Moderate Ulcerative Colitis: Your Role in Patient Compliance and Health Care Costs. Journal of Managed Care Pharmacy, 2007, 13, 2-15.	2.2	18
14	MMX Multi Matrix System [®] mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Alimentary Pharmacology and Therapeutics, 2007, 26, 205-215.	1.9	156
15	Adherence to thiopurine treatment in outpatients with Crohn's disease. Alimentary Pharmacology and Therapeutics, 2007, 26, 217-225.	1.9	63
16	Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates. Alimentary Pharmacology and Therapeutics, 2007, 26, 1179-1186.	1.9	14
17	Release of 5-aminosalicylate from an MMX mesalamine tablet during transit through a simulated gastrointestinal tract system. Advances in Therapy, 2007, 24, 826-840.	1.3	51
18	Optimizing drug therapy in inflammatory bowel disease. Current Gastroenterology Reports, 2007, 9, 513-520.	1.1	12
19	Optimizing conventional therapy for inflammatory bowel disease. Current Gastroenterology Reports, 2008, 10, 585-590.	1.1	22
20	Quality of life of patients with ulcerative colitis: Past, present, and future. Inflammatory Bowel Diseases, 2008, 14, 554-565.	0.9	125

#	ARTICLE	IF	CITATIONS
21	Cut instincts: Explorations in intestinal physiology and drug delivery. International Journal of Pharmaceutics, 2008, 364, 213-226.	2.6	394
22	Endoscopic healing should be a goal for everyone with ulcerative colitis. Inflammatory Bowel Diseases, 2008, , NA-NA.	0.9	12
23	Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2008, 27, 15-21.	1.9	31
24	MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Alimentary Pharmacology and Therapeutics, 2008, 27, 1094-1102.	1.9	53
25	Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis – methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa. Alimentary Pharmacology and Therapeutics, 2008, 28, 663-673.	1.9	61
26	Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2008, 28, 815-829.	1.9	15
27	The involvement of heme oxygenase-1 activity in the therapeutic actions of 5-aminosalicylic acid in rat colitis. European Journal of Pharmacology, 2008, 581, 315-323.	1.7	68
28	Once daily 5-aminosalicylic acid for the treatment of ulcerative colitis; are we there yet?. Pharmacological Research, 2008, 58, 190-195.	3.1	18
29	Improving Delivery of Aminosalicylates in Ulcerative Colitis. Drugs, 2008, 68, 1089-1103.	4.9	27
31	P038 AN OPEN-LABEL TRIAL OF INFlixIMAB FOR INDUCING AND MAINTAINING CLINICAL AND ENDOSCOPIC REMISSION IN PATIENTS WITH ACUTE, SEVERE ULCERATIVE COLITIS. Journal of Crohn S and Colitis Supplements, 2008, 2, 16-17.	0.0	0
32	P039 DOES IMMUNOGENICITY PLAY A ROLE IN ADALIMUMAB TREATMENT FOR CROHN'S DISEASE?. Journal of Crohn S and Colitis Supplements, 2008, 2, 17.	0.0	0
33	P040 ONCE-OR TWICE-DAILY MMX MESALAZINE (2.4G/DAY) IS EFFECTIVE FOR THE MAINTENANCE OF REMISSION OF MILD-TO-MODERATE ULCERATIVE COLITIS REGARDLESS OF THE MESALAZINE DOSE OR REGIMEN USED TO INDUCE REMISSION. Journal of Crohn S and Colitis Supplements, 2008, 2, 17.	0.0	0
34	European evidence-based Consensus on the management of ulcerative colitis: Current management. Journal of Crohn's and Colitis, 2008, 2, 24-62.	0.6	473
35	Delayed-release MMX mesalazine: a guide to its use in ulcerative colitis. Drugs and Therapy Perspectives, 2008, 24, 6-8.	0.3	0
36	Mesalamine with MMX technology for the treatment of ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2008, 2, 299-314.	1.4	8
37	Multi-Matrix System Mesalamine: To Use or Not To Use. Annals of Pharmacotherapy, 2008, 42, 265-269.	0.9	11
38	Inflammatory Bowel Disease in Older People. Journal of Pharmacy Practice and Research, 2008, 38, 234-238.	0.5	1
39	Cost-Effectiveness of 5-Aminosalicylic Acid Therapy for Maintenance of Remission in Ulcerative Colitis. American Journal of Gastroenterology, 2008, 103, 3094-3105.	0.2	29

#	ARTICLE	IF	CITATIONS
40	Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. <i>Gut</i> , 2008, 57, 893-902.	6.1	151
41	MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1049-1058.	0.9	17
42	Specific considerations in the treatment of pediatric inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 105-124.	1.4	9
43	Novel 5-Aminosalicylic Acid Formulations in Ulcerative Colitis. <i>Gastroenterology Nursing</i> , 2008, 31, 286-292.	0.2	2
45	Therapy of ulcerative colitis: state of the art. <i>Current Opinion in Gastroenterology</i> , 2008, 24, 469-474.	1.0	16
46	Oral 5-ASA Therapy in Ulcerative Colitis. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 338-344.	1.1	31
47	Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial. <i>Patient Preference and Adherence</i> , 2008, 2, 253.	0.8	22
48	New treatment options for patients with ulcerative colitis. <i>Gastrointestinal Nursing</i> , 2008, 6, 27-31.	0.0	2
49	Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine. <i>Patient Preference and Adherence</i> , 2009, 3, 87.	0.8	2
50	Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease. <i>Clinical and Experimental Gastroenterology</i> , 2009, 2, 139.	1.0	5
51	A transatlantic comparison of nurse-led, patient-centred care for ulcerative colitis. <i>Gastrointestinal Nursing</i> , 2009, 7, 43-47.	0.0	0
52	Mesalazine for ulcerative colitis: evidence for use. <i>NursePrescribing</i> , 2009, 7, 352-356.	0.1	0
53	Current Strategies for the Treatment of Ulcerative Colitis. <i>Recent Patents on Inflammation and Allergy Drug Discovery</i> , 2009, 3, 65-72.	3.9	14
54	A Review of Delayed-Release MMX Mesalamine: It's Use in the Treatment of Ulcerative Colitis. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2293.	0.1	0
55	A Review of Multimatrix System (MMX) Mesalazine in the Management of Ulcerative Colitis. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S38.	0.1	1
56	Safety and Efficacy of a New 3.3% b.i.d. Tablet Formulation in Patients With Mild-to-Moderately-Active Ulcerative Colitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. <i>American Journal of Gastroenterology</i> , 2009, 104, 1452-1459.	0.2	45
57	Medical Management of Ulcerative Colitis. <i>Digestive Diseases</i> , 2009, 27, 542-549.	0.8	21
58	MMX Mesalamine is Safe and Efficacious in Achieving Clinical and Endoscopic Remission of Active Ulcerative Colitis. <i>Hospital Practice (1995)</i> , 2009, 37, 159-161.	0.5	0

#	ARTICLE	IF	CITATIONS
59	New approaches to adherence issues when dosing oral aminosalicylates in ulcerative colitis. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 451-457.	0.5	8
60	Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. <i>Gut</i> , 2009, 58, 233-240.	6.1	171
61	Recent advances in the management of inflammatory bowel disease. <i>Clinical Medicine</i> , 2009, 9, 605-608.	0.8	1
62	Effect of extended MMX mesalamine therapy for acute, mild-to-moderate Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1-8.	0.9	78
63	Impact of ulcerative colitis from patients' and physicians' perspectives. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 581-588.	0.9	87
64	Therapeutic strategies for the management of ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 935-950.	0.9	65
66	Optimizing conventional therapies for inflammatory bowel disease. <i>Current Gastroenterology Reports</i> , 2009, 11, 496-503.	1.1	11
67	Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes?. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 459-469.	1.9	56
68	Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX [®] with Asacol [®] . <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 908-918.	1.9	77
69	Emerging drugs for the treatment of ulcerative colitis. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 505-521.	1.0	24
70	The long journey of salicylates in ulcerative colitis: The past and the future. <i>Journal of Crohn's and Colitis</i> , 2009, 3, 149-156.	0.6	31
71	Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis. <i>Gastroenterology</i> , 2009, 137, 1934-1943.e3.	0.6	148
72	Accidentally ASCENDING Into Comparative Effective Research for Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2009, 137, 1880-1882.	0.6	6
74	Evolving Inflammatory Bowel Disease Treatment Paradigms: Top-Down Versus Step-Up. <i>Gastroenterology Clinics of North America</i> , 2009, 38, 577-594.	1.0	22
75	Mesalamine Once Daily Is More Effective Than Twice Daily in Patients With Quiescent Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 762-769.	2.4	130
76	Ulcerative colitis: current medical therapy and strategies for improving medication adherence. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 1-8.	0.8	19
77	Induction of clinical and endoscopic remission in mild-to-moderate ulcerative colitis in patients treated with MMX [®] mesalamine: established versus newly diagnosed disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, S34.	0.9	1
78	Continued persistence with mesalamine therapy in long-term persistent patients: Results from a large pharmacy database. <i>Inflammatory Bowel Diseases</i> , 2009, 15, S35.	0.9	0

#	ARTICLE	IF	CITATIONS
79	Induction of mucosal healing in mild-to-moderate ulcerative colitis in patients treated with MMX mesalamine: established versus newly diagnosed disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, S35.	0.9	1
82	Factors influencing persistence with mesalamine therapy: Results from a large pharmacy database. <i>Inflammatory Bowel Diseases</i> , 2009, 15, S35.	0.9	0
83	Gastrointestinal drugs. <i>Side Effects of Drugs Annual</i> , 2010, 32, 665-674.	0.6	0
84	Inducing and Maintaining Remission in Ulcerative Colitis. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 531-535.	1.1	13
85	Dynamic Dissolution: A Step Closer to Predictive Dissolution Testing?. <i>Molecular Pharmaceutics</i> , 2010, 7, 1374-1387.	2.3	118
86	Mucosal Healing in Inflammatory Bowel Disease: Where Do We Stand?. <i>Current Gastroenterology Reports</i> , 2010, 12, 471-478.	1.1	44
87	Importance of mucosal healing in ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 338-346.	0.9	199
88	Clinical scenarios in IBD: Optimizing the use of conventional and biologic agents. <i>Inflammatory Bowel Diseases</i> , 2010, 16, S1-S11.	0.9	16
89	Oral 5-aminosalicylic acid therapy for mild-to-moderate ulcerative colitis. <i>Journal of the American Academy of Nurse Practitioners</i> , 2010, 22, 586-592.	1.4	2
90	Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6-month placebo-controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 990-999.	1.9	50
91	Unpromoted issues in inflammatory bowel disease: opportunities to optimize care. <i>Internal Medicine Journal</i> , 2010, 40, 173-182.	0.5	44
92	Advances in the management of inflammatory bowel disease. <i>Internal Medicine Journal</i> , 2010, 40, 258-264.	0.5	18
93	Consensus guidelines for the management of inflammatory bowel disease. <i>Arquivos De Gastroenterologia</i> , 2010, 47, 313-325.	0.3	35
94	A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective. <i>Journal of Medical Economics</i> , 2010, 13, 148-161.	1.0	19
95	New Drug Delivery Systems in Inflammatory Bowel Disease: MMX and Tailored Delivery to the Gut. <i>Current Medicinal Chemistry</i> , 2010, 17, 1851-1857.	1.2	39
96	Pros and Cons of Medical Management of Ulcerative Colitis. <i>Clinics in Colon and Rectal Surgery</i> , 2010, 23, 227-238.	0.5	9
97	Efficacy and safety of drugs for ulcerative colitis. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 573-592.	1.0	38
98	Clinical Pharmacology of 5-ASA Compounds in Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2010, 39, 559-599.	1.0	41

#	ARTICLE	IF	CITATIONS
99	Evolving Inflammatory Bowel Disease Treatment Paradigms: Top-Down Versus Step-Up. <i>Medical Clinics of North America</i> , 2010, 94, 1-18.	1.1	33
100	Once-Daily Dosing of Delayed-Release Oral Mesalamine (400-mg Tablet) Is as Effective as Twice-Daily Dosing for Maintenance of Remission of Ulcerative Colitis. <i>Gastroenterology</i> , 2010, 138, 1286-1296.e3.	0.6	125
101	New light on the anti-colitic actions of therapeutic aminosalicylates: the role of heme oxygenase. <i>Pharmacological Reports</i> , 2010, 62, 548-556.	1.5	16
102	Clinical implications of mucosal healing for the management of IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 15-29.	8.2	415
105	We Once Were Blind and Now We See: Is it Time to Treat Ulcerative Colitis to Achieve Mucosal Healing?. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 456-457.	2.4	10
106	High-dose mesalazine treatment for ulcerative colitis patients who relapse under low-dose maintenance therapy. <i>Digestive and Liver Disease</i> , 2011, 43, 386-390.	0.4	9
107	An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2011, 106, S2-S25.	0.2	244
108	Cost Effectiveness of Treatments for Inflammatory Bowel Disease. <i>Pharmacoeconomics</i> , 2011, 29, 387-401.	1.7	34
109	MMX [®] Mesalazine. <i>Drugs</i> , 2011, 71, 221-235.	4.9	16
110	Plasma pharmacokinetics and gastrointestinal transit of a new Propionyl-L-Carnitine controlled release formulation. <i>Xenobiotica</i> , 2011, 41, 988-995.	0.5	7
111	Aminosalicylates. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 535-546.	1.0	32
112	Guidelines for the management of inflammatory bowel disease in adults. <i>Gut</i> , 2011, 60, 571-607.	6.1	1,127
113	In Vitro Testing of Controlled Release Dosage Forms During Development and Manufacture. , 2011, , 91-108.		2
114	Once Daily, High-Dose Mesalazine Controlled-Release Tablet for Colonic Delivery: Optimization of Formulation Variables Using Box-Behnken Design. <i>AAPS PharmSciTech</i> , 2011, 12, 1454-1464.	1.5	12
116	Mucosal Healing in Ulcerative Colitis: Where do we Stand?. <i>Current Drug Targets</i> , 2011, 12, 1417-1423.	1.0	17
117	Methotrexate: A Drug of the Future in Ulcerative Colitis?. <i>Current Drug Targets</i> , 2011, 12, 1413-1416.	1.0	7
118	Randomised clinical trial: delayed-release oral mesalazine 4.8â€ƒg/day vs. 2.4â€ƒg/day in endoscopic mucosal healing - ASCEND I and II combined analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 672-678.	1.9	79
119	Endoscopic mucosal healing in ulcerative colitis: authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 1255-1256.	1.9	0

#	ARTICLE	IF	CITATIONS
120	Review article: defining remission in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 113-124.	1.9	180
121	Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis - additional results from two controlled studies. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 747-756.	1.9	27
122	Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1115-1122.	1.9	26
123	Layered lipid microcapsules for mesalazine delayed-release in children. <i>International Journal of Pharmaceutics</i> , 2011, 421, 293-300.	2.6	20
124	Update on the Management of Ulcerative Colitis. <i>Current Gastroenterology Reports</i> , 2011, 13, 475-485.	1.1	18
125	Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine. <i>BMC Health Services Research</i> , 2011, 11, 157.	0.9	17
126	New desensitization regimen with mesalamine granules in a patient with ulcerative colitis and mesalamine intolerance. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E8-E9.	0.9	10
129	Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , 2011, 4, 129-143.	1.4	47
130	Current misunderstandings in the management of ulcerative colitis. <i>Gut</i> , 2011, 60, 1294-1299.	6.1	39
131	Once-Daily MMX Mesalamine in the Management of Ulcerative colitis. <i>Clinical Medicine Gastroenterology</i> , 2011, 4, CGast.S4276.	0.2	0
132	Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , 2011, 4, 237-248.	1.4	103
133	Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis?. <i>Current Drug Targets</i> , 2011, 12, 1396-1405.	1.0	30
134	Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 601-616.	0.2	231
135	Optimization of conventional therapy in patients with IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 646-656.	8.2	66
136	Once-Daily Dosing vs. Conventional Dosing Schedule of Mesalamine and Relapse of Quiescent Ulcerative Colitis: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 2070-2077.	0.2	52
137	Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). <i>Gut</i> , 2012, 61, 535-542.	6.1	463
139	Once-Daily MMX [®] Mesalamine for Endoscopic Maintenance of Remission of Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2012, 107, 1064-1077.	0.2	39
140	Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. , 2012, 10, CD000543.		103

#	ARTICLE	IF	CITATIONS
141	Editorial (Hot Topic :Randomized Clinical Trials in Inflammatory Bowel Disease). Reviews on Recent Clinical Trials, 2012, 7, 255-255.	0.4	0
142	Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials. European Journal of Gastroenterology and Hepatology, 2012, 24, 487-494.	0.8	7
143	Conventional Medical Management of Ulcerative Colitis: Sulfasalazine and 5-Aminosalicylates. , 2012, , 453-466.		1
144	Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis. Expert Opinion on Pharmacotherapy, 2012, 13, 2225-2232.	0.9	4
145	Mucosal healing in inflammatory bowel diseases: a systematic review. Gut, 2012, 61, 1619-1635.	6.1	673
146	Once-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study. Gastroenterology, 2012, 143, 1218-1226.e2.	0.6	213
147	Mesalazine in left-sided ulcerative colitis: Efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. Journal of Crohn's and Colitis, 2012, 6, 476-482.	0.6	30
148	Treatment of inflammatory bowel diseases: To heal the wound or to heal the sick?. Journal of Crohn's and Colitis, 2012, 6, 621-625.	0.6	7
149	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. Journal of Crohn's and Colitis, 2012, 6, 991-1030.	0.6	1,106
150	Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine. Clinical Pharmacology: Advances and Applications, 2012, 4, 41.	0.8	14
152	Strategies in maintenance for patients receiving long-term therapy (SIMPLE): A study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis*. Inflammatory Bowel Diseases, 2012, 18, 1026-1033.	0.9	27
153	One-year investigator-blind randomized multicenter trial comparing asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflammatory Bowel Diseases, 2012, 18, 1885-1893.	0.9	22
154	High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: Results of a meta-analysis of clinical trials. Inflammatory Bowel Diseases, 2012, 18, 2190-2198.	0.9	43
155	Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: A systematic review and meta-analysis. Inflammatory Bowel Diseases, 2012, 18, 1785-1794.	0.9	49
156	Onceâ€daily <i>versus</i> multipleâ€daily mesalamine for patients with ulcerative colitis: A metaâ€analysis. Journal of Digestive Diseases, 2012, 13, 200-207.	0.7	12
157	The impact of <sc>MMX</sc> mesalazine on diseaseâ€specific healthâ€related quality of life in ulcerative colitis patients. Alimentary Pharmacology and Therapeutics, 2012, 35, 1386-1396.	1.9	14
158	Impact of MMX® Mesalamine on Improvement and Maintenance of Health-Related Quality of Life in Patients with Ulcerative Colitis. Inflammatory Bowel Diseases, 2013, 19, 386-396.	0.9	7
159	The Role of Centralized Reading of Endoscopy in a Randomized Controlled Trial of Mesalamine for Ulcerative Colitis. Gastroenterology, 2013, 145, 149-157.e2.	0.6	196

#	ARTICLE	IF	CITATIONS
160	Recent developments in the treatment of inflammatory bowel disease. <i>Journal of Digestive Diseases</i> , 2013, 14, 282-287.	0.7	30
161	Comparison of am colon capsule endoscopy versus conventional colonoscopy for the detection of severity and extent of ulcerative colitis. <i>Journal of Digestive Diseases</i> , 2013, 14, 117-124.	0.7	53
162	Looking Forward to Understanding and Reducing Colorectal Cancer Risk in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2013, 145, 47-49.	0.6	3
163	The effect of third-party reporting on adoption of evidence-based mesalazine regimens in ulcerative colitis: An observational study. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e125-e132.	0.6	1
164	The GETECCU clinical guideline for the treatment of ulcerative colitis: A guideline created using GRADE methodology. <i>Gastroenterology & Hepatology</i> , 2013, 36, 483.e1-483.e46.	0.2	2
166	What You See is Not Always What You Get: Raising the Bar on Clinical Trial Methodology in Ulcerative Colitis. <i>Gastroenterology</i> , 2013, 145, 45-47.	0.6	3
167	Reply. <i>Gastroenterology</i> , 2013, 144, e23-e24.	0.6	0
168	Review article: strategies for the management of chronic unremitting ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 77-97.	1.9	34
169	Mesalazine for the treatment of inflammatory bowel disease. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1669-1678.	0.9	35
170	New targeting strategies in drug therapy of inflammatory bowel disease: mechanistic approaches and opportunities. <i>Expert Opinion on Drug Delivery</i> , 2013, 10, 1275-1286.	2.4	22
171	Are Endoscopic Endpoints Reliable in Therapeutic Trials of Ulcerative Colitis?. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2611-2615.	0.9	10
172	Drug advances in inflammatory bowel disease. <i>Clinical Medicine</i> , 2013, 13, 378-382.	0.8	10
173	Treatment of Ulcerative Colitis in the Elderly: A Systematic Review. <i>Clinical Medicine Insights: Geriatrics</i> , 2013, 6, 1-26.	0.0	4
174	Randomised clinical trial: once vs. twice daily prolonged release mesalazine for active ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 767-775.	1.9	58
175	Clinical aspects of mucosal healing in inflammatory bowel diseases: what is it and what is the real value for the everyday practice?. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 871-882.	1.3	0
176	Steroids and 5-aminosalicylic acids in moderate ulcerative colitis: addressing the dilemma. <i>Therapeutic Advances in Gastroenterology</i> , 2013, 6, 33-38.	1.4	16
177	Are There Any Differences in the Efficacy and Safety of Different Formulations of Oral 5-ASA Used for Induction and Maintenance of Remission in Ulcerative Colitis? Evidence from Cochrane Reviews. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1.	0.9	55
178	Mucosal Healing in Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 212-221.	1.1	48

#	ARTICLE	IF	CITATIONS
179	Dissolution Criticality in Developing Solid Oral Formulations: From Inception to Perception. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2013, 30, 495-534.	1.2	9
180	Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis. <i>Clinical and Experimental Gastroenterology</i> , 2014, 7, 369.	1.0	23
181	Maintenance of Remission in Ulcerative Colitis. , 2014, , 417-430.		1
182	Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. <i>Gut</i> , 2014, 63, 433-441.	6.1	222
183	Aligning oral mesalazine treatment to health service priorities: guidance for nurses. <i>Frontline Gastroenterology</i> , 2014, 5, 135-142.	0.9	0
184	eHealth. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2276-2285.	0.9	81
185	The Importance of Mucosal Healing in Ulcerative Colitis. , 2014, , 45-54.		0
186	Review article: integrating budesonideâ€œMMX into treatment algorithms for mildâ€œtoâ€œmoderate ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1095-1103.	1.9	52
187	Fecal Calprotectinâ€œGuided Dosing of Mesalamine in Ulcerative Colitis: Concept Proved but More Data Needed. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1894-1896.	2.4	2
188	Mucosal Healing As a Target of Therapy for Colonic Inflammatory Bowel Disease and Methods to Score Disease Activity. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2014, 24, 367-378.	0.6	101
189	Su1280 The Modified Mayo Endoscopic Score (MMES): A New Score for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis (UC) Patients. <i>Gastroenterology</i> , 2014, 146, S-424.	0.6	0
190	New Applications for Traditional Drugs in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2948-2957.	0.9	3
191	Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1200-1210.	1.9	115
192	Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2015, 6, 137.	0.6	67
194	Management of Mild-to-Moderate Ulcerative Colitis. <i>Digestive Diseases</i> , 2015, 33, 90-94.	0.8	3
195	Induction of clinical and colonoscopic remission of mildâ€œtoâ€œmoderate ulcerative colitis with budesonide MMX 9Âµg: pooled analysis of two phase 3 studies. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 409-418.	1.9	63
196	The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 846-852.	0.6	108
197	Medical Therapy of Active Ulcerative Colitis. <i>Visceral Medicine</i> , 2015, 31, 236-245.	0.5	6

#	ARTICLE	IF	CITATIONS
199	Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016, 7, 5.	0.6	39
200	Once daily <i>vs</i> multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis. <i>Colorectal Disease</i> , 2016, 18, O214-23.	0.7	17
201	Oral or Topical 5-ASA in Ulcerative Colitis. <i>Digestive Diseases</i> , 2016, 34, 122-124.	0.8	12
202	Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1-13.	1.4	64
203	Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Active Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study. <i>Advances in Therapy</i> , 2016, 33, 400-409.	1.3	7
204	Patient Reported Outcome Measures (PROMs) in Inflammatory Bowel Disease: New Data. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw187.	0.6	40
205	Head-to-head comparative studies: Challenges & opportunities?. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw167.	0.6	6
206	Maintenance therapy options for ulcerative colitis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1339-1349.	0.9	20
207	Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2016, 4, CD000543.	1.5	202
208	Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice. <i>Current Gastroenterology Reports</i> , 2016, 18, 5.	1.1	29
209	Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 925-933.	0.6	24
210	Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1245-1255.e8.	2.4	255
211	Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 607-618.	0.6	39
212	Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 358-370.	1.1	31
213	Aminosalicylates. , 2016, , 242-254.		0
214	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2017, 49, 338-358.	0.4	42
215	Experiencia clínica en el tratamiento con mesalazina MMX en monoterapia en los pacientes con colitis ulcerosa. <i>Enfermedad Inflamatoria Intestinal Al DÁa</i> , 2017, 16, 45-50.	0.2	0
216	Sulfasalazine and 5-Aminosalicylates for Ulcerative Colitis. , 2017, , 389-397.		1

#	ARTICLE	IF	CITATIONS
217	Randomised non-inferiority trial: 1600Âmg versus 400Âmg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 292-302.	1.9	29
218	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 769-784.	0.6	876
219	Objective Assessment of Endoscopic Disease Activity and Mucosal Healing. , 2017, , 267-277.		2
220	Measurement of <i>in vivo</i> Gastrointestinal Release and Dissolution of Three Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract. <i>Molecular Pharmaceutics</i> , 2017, 14, 345-358.	2.3	39
221	Nanoparticulate drug delivery systems targeting inflammation for treatment of inflammatory bowel disease. <i>Nano Today</i> , 2017, 16, 82-96.	6.2	136
222	Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 773-790.	1.4	22
223	MMX^{Â®} technology and its applications in gastrointestinal diseases. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 545-552.	1.4	24
224	Regulatory framework on bioequivalence criteria for locally acting gastrointestinal drugs: the case for oral modified release mesalamine formulations. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1007-1019.	1.3	5
225	The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 33-41.	1.4	7
226	Role of synbiotics in polysaccharide assisted colon targeted microspheres of mesalamine for the treatment of ulcerative colitis. <i>International Journal of Biological Macromolecules</i> , 2017, 95, 438-450.	3.6	41
227	Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. <i>The Cochrane Library</i> , 2017, 9, CD011572.	1.5	13
228	Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. <i>Intestinal Research</i> , 2017, 15, 266.	1.0	34
229	Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study. <i>Intestinal Research</i> , 2017, 15, 368.	1.0	9
230	Second Korean guidelines for the management of ulcerative colitis. <i>Intestinal Research</i> , 2017, 15, 7.	1.0	59
232	Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 450-463.	0.9	10
233	Multi Matrix System Mesalazine Plus Rectal Mesalazine in the Treatment of Mild to Moderately Active Ulcerative Proctitis. <i>Digestive Diseases</i> , 2018, 36, 130-135.	0.8	4
234	Systematic review: safety of mesalazine in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1597-1609.	1.9	90
235	Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study. <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 22.	0.9	5

#	ARTICLE	IF	CITATIONS
236	Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1578-1596.	1.9	31
237	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 637-647.e13.	2.4	44
238	Mesalazine-Induced Cardiotoxicity. <i>Journal of Rare Disorders Diagnosis & Therapy</i> , 2018, 04, .	0.1	0
239	Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 1079-1100.	1.4	14
240	Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study. <i>Intestinal Research</i> , 2018, 16, 255.	1.0	8
241	Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 742-753.	3.7	40
242	Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands. <i>Journal of Medical Economics</i> , 2018, 21, 869-877.	1.0	4
243	Endoscopic Diagnosis and Staging of Inflammatory Bowel Disease. , 2019, , 425-434.e2.		0
244	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. <i>Clinical Pharmacokinetics</i> , 2019, 58, 15-37.	1.6	91
245	Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2244-2254.	1.1	10
246	A comprehensive review and update on ulcerative colitis,. <i>Disease-a-Month</i> , 2019, 65, 100851.	0.4	264
247	Efficacy of co-administration of modified apple polysaccharide and probiotics in guar gum-Eudragit S100 based mesalamine mini tablets: A novel approach in treating ulcerative colitis. <i>International Journal of Biological Macromolecules</i> , 2019, 126, 427-435.	3.6	34
248	AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. <i>Gastroenterology</i> , 2019, 156, 748-764.	0.6	194
249	AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. <i>Gastroenterology</i> , 2019, 156, 769-808.e29.	0.6	88
250	The impact of food intake on the luminal environment and performance of oral drug products with a view to <i>in vitro</i> and <i>in silico</i> simulations: a PEARRL review. <i>Journal of Pharmacy and Pharmacology</i> , 2019, 71, 557-580.	1.2	51
251	Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 98-106.e4.	2.4	18
252	Mesalamine in the Initial Therapy of Ulcerative Colitis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 689-704.	1.0	9
253	Solving the questions regarding 5-aminosalicylate formulation in the treatment of ulcerative colitis. <i>Journal of Gastroenterology</i> , 2020, 55, 1013-1022.	2.3	7

#	ARTICLE	IF	CITATIONS
254	Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. The Cochrane Library, 2020, CD000543.	1.5	22
255	Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. Journal of Clinical Medicine, 2020, 9, 2905.	1.0	11
256	Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis. Journal of Crohn's and Colitis, 2020, 14, 1274-1281.	0.6	3
257	Head-to-head trials in inflammatory bowel disease: past, present and future. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 365-376.	8.2	37
258	Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 637-645.	1.4	47
259	Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis. Journal of Crohn's and Colitis, 2021, 15, 1184-1196.	0.6	26
260	Evaluation of the efficacy of MMX mesalazine therapy for moderate ulcerative colitis. Meditsinskiy Sovet, 2021, , 113-123.	0.1	3
261	Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis. Current Medical Research and Opinion, 2021, 37, 1891-1900.	0.9	10
262	Contrast and Comparison of Mesalamine Derivatives in the Treatment of Ulcerative Colitis. , 2014, , 69-99.		1
264	GuÃa GETECCU 2020 para el tratamiento de la colitis ulcerosa. Elaborada con metodologÃa GRADE. GastroenterologÃa Y HepatologÃa, 2020, 43, 1-57.	0.2	24
265	Deep learning enabled classification of Mayo endoscopic subscore in patients with ulcerative colitis. European Journal of Gastroenterology and Hepatology, 2021, 33, 645-649.	0.8	33
266	5ÃaminosalicylateÃintolerant patients are at increased risk of colectomy for ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2021, 53, 103-113.	1.9	10
267	Hypoxia-dependent regulation of inflammatory pathways in immune cells. Journal of Clinical Investigation, 2016, 126, 3716-3724.	3.9	151
268	Remission endpoints in ulcerative colitis: A systematic review. World Journal of Meta-analysis, 2017, 5, 85.	0.1	5
269	The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial. PLoS ONE, 2014, 9, e116306.	1.1	56
270	Role of Fecal Calprotectin as a Noninvasive Indicator for Ulcerative Colitis Disease Activity. Folia Medica, 2019, 61, 188-196.	0.2	3
271	Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis: Is there anything new under the sun?. World Journal of Gastroenterology, 2009, 15, 1799.	1.4	13
272	5-ASA in ulcerative colitis: Improving treatment compliance. World Journal of Gastroenterology, 2009, 15, 4353.	1.4	26

#	ARTICLE	IF	CITATIONS
273	Understanding of chemoprophylaxis and concordance in inflammatory bowel disease. World Journal of Gastroenterology, 2010, 16, 578.	1.4	6
274	Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease. World Journal of Gastroenterology, 2011, 17, 3467.	1.4	30
275	Presence of phthalates in gastrointestinal medications: Is there a hidden danger?. World Journal of Gastroenterology, 2013, 19, 7042.	1.4	33
276	Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World Journal of Gastroenterology, 2015, 21, 8776.	1.4	12
277	Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?. World Journal of Gastroenterology, 2017, 23, 6385-6402.	1.4	51
278	Refractory Ulcerative Proctitisâ€”A Brief Review. Open Journal of Gastroenterology, 2016, 06, 239-248.	0.1	1
279	â€œMucosal healingâ€”in ulcerative colitis: Between clinical evidence and market suggestion. World Journal of Gastrointestinal Pathophysiology, 2014, 5, 54.	0.5	7
280	Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy. World Journal of Gastrointestinal Pathophysiology, 2016, 7, 1.	0.5	17
281	Recent advances in the management of distal ulcerative colitis. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2010, 1, 43.	0.6	28
282	Guidelines for the Management of Ulcerative Colitis. Intestinal Research, 2012, 10, 1.	1.0	12
283	Is once daily multimatrix mesalazine therapy effective regardless of the dose in patients with mild to moderate ulcerative colitis?. Intestinal Research, 2018, 16, 163.	1.0	1
284	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. Journal of Crohn's and Colitis, 2022, 16, 2-17.	0.6	288
286	State of the Art Medical Treatment of the Adult Patient with IBD: The Mesalamine-Based Therapies. , 2011, , 59-71.		0
287	Oral/Rectal or Combination 5-Aminosalicylic Acid?. , 2011, , 31-34.		0
289	The History of Medical Therapy of Ulcerative Colitis. , 2014, , 1-14.		1
290	Step-Up Versus Top-Down Therapy in Ulcerative Colitis. , 2014, , 457-467.		0
292	Assessment of Disease Activity in Ulcerative Colitis. , 2014, , 345-357.		0
294	Medical Treatment of Ulcerative Colitis: Does Traditional Therapy Still Have a Role?. Updates in Surgery Series, 2019, , 93-104.	0.0	0

#	ARTICLE	IF	CITATIONS
295	Medikamentöse Therapie der Colitis ulcerosa und Pouchitis. , 2020 , 285-303.		2
296	Medikamentöse Therapie der CED bei Kindern und Jugendlichen. , 2020 , 393-425.		0
297	Budding Multi-matrix Technology – a Retrospective Approach, Deep Insights, and Future Perspectives. AAPS PharmSciTech, 2021, 22, 264.	1.5	3
298	Mild-to-moderate left-sided ulcerative colitis and proctitis. , 0 , 189-207.		0
299	Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis. Therapeutics and Clinical Risk Management, 2007, 3, 919-27.	0.9	9
300	Limitations in assessment of mucosal healing in inflammatory bowel disease. World Journal of Gastroenterology, 2010, 16, 15-20.	1.4	11
301	New Research in Ulcerative Colitis: Optimizing 5-ASA Administration for Efficacy and Adherence. Gastroenterology and Hepatology, 2010, 6, 4-16.	0.2	2
302	5-ASA Dose-Response: Maximizing Efficacy and Adherence. Gastroenterology and Hepatology, 2010, 6, 1-16.	0.2	3
303	Mesalamine-induced Pneumonitis and Serum Sickness-like Reaction. Gastroenterology and Hepatology, 2007, 3, 875-7.	0.2	5
304	Targeting mucosal healing in Crohn's disease. Gastroenterology and Hepatology, 2011, 7, 374-80.	0.2	8
305	Medical Management of Ulcerative Colitis. , 2022 , 765-779.		0
306	Clinical translation of advanced colonic drug delivery technologies. Advanced Drug Delivery Reviews, 2022, 181, 114076.	6.6	51
307	A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation. Journal of Gastroenterology, 2022, 57, 246-266.	2.3	22
310	Is it time to include older adults in inflammatory bowel disease trials? A call for action. The Lancet Healthy Longevity, 2022, 3, e356-e366.	2.0	14
311	Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial. Journal of Crohn's and Colitis, 2022, 16, 1714-1724.	0.6	4
312	Endoscopic activity in inflammatory bowel disease: clinical significance and application in practice. Clinical Endoscopy, 2022, 55, 480-488.	0.6	5
313	Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review. United European Gastroenterology Journal, 2022, 10, 854-867.	1.6	8
314	Comparative evaluation of the effectiveness of monotherapy of ulcerative colitis with mesalazine MMX and combination therapy with non-prolonged mesalazines with rectal forms. Meditsinskiy Sovet, 2022 , 96-106.	0.1	0

#	ARTICLE	IF	CITATIONS
315	Most Placebo-Controlled Trials in Inflammatory Bowel Disease were Underpowered Because of Overestimated Drug Efficacy Rates: Results from a Systematic Review of Induction Studies. <i>Journal of Crohn's and Colitis</i> , 2023, 17, 404-417.	0.6	3
316	Comparative Effectiveness Research: A Roadmap to Sail the Seas of IBD Therapies. <i>Journal of Clinical Medicine</i> , 2022, 11, 6717.	1.0	2
317	Colonic drug delivery: Formulating the next generation of colon-targeted therapeutics. <i>Journal of Controlled Release</i> , 2023, 353, 1107-1126.	4.8	36
319	Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. <i>Przegląd Gastroenterologiczny</i> , 2023, 18, 1-42.	0.3	1